Chronic Myeloid Leukemia Market 2022
Edoardo Lombarda
2014-02-26
Views 1
Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-chronic-myeloid-leukemia-cml-global-drug-forecast-and-market-analysis-to-2022-market-report.html .
Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients’ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems
Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients’ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems
Report form
RELATED VIDEOS
